Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FX 06

Next Previous
X
Search
Drug Profile

FX 06

Alternative Names: FX 06-RI; FX 06-SS; FX06; FX06 HS; FX06 MRI; Peptide Bβ15-42

Latest Information Update: 01 Feb 2022

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FIBREX Medical; Medical University of Vienna
  • Developer Assistance Publique Hopitaux de Paris; F4 Pharma; FIBREX Medical
  • Class Anti-inflammatories; Peptides
  • Mechanism of Action Cadherin 5 modulators; Fibrin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Capillary leak syndrome; SARS-CoV-2 acute respiratory disease; Vascular disorders
  • No development reported Delayed graft function
  • Discontinued Reperfusion injury

Most Recent Events

  • 06 Dec 2021 Phase-II clinical trials in SARS-COV-2 acute respiratory disease in Germany (IV) (EudraCT2021-005059-35)
  • 13 Jun 2021 F4 Pharma and Assistance Publique Hopitaux de Paris completes the phase II FX-COVID trial in SARS-COV-2 acute respiratory disease in France (NCT04618042)
  • 03 Mar 2021 Phase-II clinical trials in Capillary leak syndrome in Austria (IV) prior to March 2021 (F4 Pharma pipeline, March 2021)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top